162 related articles for article (PubMed ID: 32476653)
1. Clinical Outcomes of Head and Neck Cancer Patients Treated with Palliative Oral Metronomic Chemotherapy at a Tertiary Cancer Center in Kerala, India.
Nv V; Muttath G; Jones J; Shringarpure K; Duraisamy K; Deenathayalan VP; Rathi P
Gulf J Oncolog; 2020 May; 1(33):68-74. PubMed ID: 32476653
[TBL] [Abstract][Full Text] [Related]
2. Metronomic palliative chemotherapy in locally advanced, recurrent and metastatic head-and-neck cancer: A single-arm, retrospective study of a regional cancer center of North India (Asia).
Harsh KK; Maharia SR; Nirban RK; Khatri P; Beniwal S; Kumar HS; Jakhar SL
J Cancer Res Ther; 2020; 16(3):559-564. PubMed ID: 32719267
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.
Patil VM; Noronha V; Joshi A; Muddu VK; Dhumal S; Bhosale B; Arya S; Juvekar S; Banavali S; D'Cruz A; Bhattacharjee A; Prabhash K
Oral Oncol; 2015 Mar; 51(3):279-86. PubMed ID: 25578869
[TBL] [Abstract][Full Text] [Related]
4. An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients.
Patil VM; Chakraborty S; Jithin TK; Sajith Babu TP; Babu S; Kumar S; Biji MS; Bhattacharjee A; Balasubramanian S
South Asian J Cancer; 2016; 5(2):48-51. PubMed ID: 27275445
[TBL] [Abstract][Full Text] [Related]
5. Triple combination of palliative oral metronomic chemotherapy in recurrent and metastatic epithelial ovarian cancer: A retrospective study.
Harsh KK; Jakhar SL; Maheshwari G; Nirban R; Kumari P; Beniwal SK; Sharma N; Kumar HS
Indian J Cancer; 2023; 60(2):167-172. PubMed ID: 37530237
[TBL] [Abstract][Full Text] [Related]
6. Comparison of paclitaxel-cetuximab chemotherapy versus metronomic chemotherapy consisting of methotrexate and celecoxib as palliative chemotherapy in head and neck cancers.
Patil VM; Noronha V; Joshi A; Agarwala V; Muddu V; Ramaswamy A; Chandrasekharan A; Dhumal S; Juvekar S; Arya A; Bhattacharjee A; Prabhash K
Indian J Cancer; 2017; 54(1):20-24. PubMed ID: 29199655
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of palliative metronomic chemotherapy in head and neck cancer.
Patil VM; Noronha V; Joshi A; Nayak L; Pande N; Chandrashekharan A; Dhumal S; Bhattacharjee A; Banavali S; Prabhash K
Indian J Cancer; 2017; 54(1):25-29. PubMed ID: 29199656
[TBL] [Abstract][Full Text] [Related]
8. Metronomic chemotherapy in advanced oral cancers.
Patil V; Noronha V; D'cruz AK; Banavali SD; Prabhash K
J Cancer Res Ther; 2012 Jan; 8 Suppl 1():S106-10. PubMed ID: 22322727
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer.
Patil VM; Noronha V; Joshi A; Dhumal S; Mahimkar M; Bhattacharjee A; Gota V; Pandey M; Menon N; Mahajan A; Sable N; Kumar S; Nawale K; Mukadam S; Solanki B; Das S; Simha V; Abraham G; Chandrasekharan A; Talreja V; DSouza H; Srinivas S; Kashyap L; Banavali S; Prabhash K
J Clin Oncol; 2019 Nov; 37(32):3032-3041. PubMed ID: 31539316
[TBL] [Abstract][Full Text] [Related]
10. A Mechanistic Review of Methotrexate and Celecoxib as a Potential Metronomic Chemotherapy for Oral Squamous Cell Carcinoma.
Kamal MV; Rao M; Damerla RR; Pai A; Sharan K; Palod A; Shetty PS; Usman N; Kumar NAN
Cancer Invest; 2023 Feb; 41(2):144-154. PubMed ID: 36269850
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of second-line erlotinib in patients postprogression of first-line chemotherapy in head and neck cancers.
Patil V; Karpe A; Noronha V; Joshi A; Muddu V; Bhattacharjee A; Dhumal S; Prabhash K
Indian J Cancer; 2015; 52(4):629-31. PubMed ID: 26960500
[TBL] [Abstract][Full Text] [Related]
12. Treatment of squamous cell carcinoma of external auditory canal: A tertiary cancer centre experience.
Gandhi AK; Roy S; Biswas A; Raza MW; Saxena T; Bhasker S; Sharma A; Thakar A; Mohanti BK
Auris Nasus Larynx; 2016 Feb; 43(1):45-9. PubMed ID: 26165629
[TBL] [Abstract][Full Text] [Related]
13. Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
Sharma A; Malik PS; Khurana S; Kumar S; Bhatla N; Ray MD; Kumar L
Indian J Med Res; 2019 Dec; 150(6):575-583. PubMed ID: 32048620
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
Weiss J; Gilbert J; Deal AM; Weissler M; Hilliard C; Chera B; Murphy B; Hackman T; Liao JJ; Grilley Olson J; Hayes DN
Oral Oncol; 2018 Sep; 84():46-51. PubMed ID: 30115475
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
[TBL] [Abstract][Full Text] [Related]
17. A molecular signature of well-differentiated oral squamous cell carcinoma reveals a resistance mechanism to metronomic chemotherapy and novel therapeutic candidates.
Kina S; Kawabata-Iwakawa R; Miyamoto S; Arasaki A; Sunakawa H; Kinjo T
J Drug Target; 2021 Dec; 29(10):1118-1127. PubMed ID: 33979258
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study.
Tiwari S; Goel V; John MC; Patnaik N; Doval DC
Indian J Cancer; 2016; 53(4):487-492. PubMed ID: 28485336
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
Kua VF; Ismail F; Chee Ee Phua V; Aslan NM
Asian Pac J Cancer Prev; 2013; 14(2):1121-6. PubMed ID: 23621198
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting.
Depenni R; Cossu Rocca M; Ferrari D; Azzarello G; Baldessari C; Alù M; Nolé F; Codecà C; Boscolo G; Piccininni M; Cavalieri S; Bossi P
Eur J Cancer; 2019 Jul; 115():4-12. PubMed ID: 31082692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
